There is a strong demand for increasingly sensitive diagnostics that are less expensive and require
a small amount of patient sample for analysis. These diagnostic tools should not only be easy to handle
for eventual laboratory automation, but they should provide improved performance over traditional detection techniques:
the ability to evaluate simultaneously multiple biomarkers at a time. Due to cancer heterogeneity, several different
tumor markers are often expressed.
XEPTAGEN is currently developing a biochip that presents a combination of non-overlapping tumor marker indicators on nano-sized platforms for simultaneous detection.